<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_medium=rss&amp;ff=20250207111255&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;utm_medium=rss&amp;ff=20250207111255&amp;v=2.18.0.post9+e462414&amp;utm_source=Chrome&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_campaign=pubmed-2" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Fri, 07 Feb 2025 16:12:56 +0000</lastbuilddate>
<pubDate>Fri, 07 Feb 2025 06:00:00 -0500</pubDate>
<ttl>120</ttl>
<item>
<title>Ezh2 Shapes T Cell Plasticity to Drive Atherosclerosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39917842/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250207111255&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our study uncovers the importance of T cell EZH2 in human and mouse atherosclerosis. Inhibition of Ezh2 in CD4^(+) T cells drives type 2 immune responses, resulting in an accumulation of iNKT2 and Th2 cells, memory T cells and anti-inflammatory macrophages that limit the progression of atherosclerosis.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 7. doi: 10.1161/CIRCULATIONAHA.124.072384. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The activation and polarization of T cells play a crucial role in atherosclerosis and dictate athero-inflammation. The epigenetic enzyme EZH2 (enhancer of zeste homolog 2) mediates the H3K27me3 (trimethylation of histone H3 lysine 27) and is pivotal in controlling T cell responses.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: To detail the role of T cell EZH2 in atherosclerosis, we used human carotid endarterectomy specimens to reveal plaque expression and geography of EZH2. Atherosclerosis-prone <i>Apoe</i> (apolipoprotein E)-deficient mice with CD (cluster of differentiation) 4<sup>+</sup> or CD8<sup>+</sup> T cell-specific <i>Ezh2</i> deletion (Ezh2<sup>cd4</sup>-knockout [KO], Ezh2<sup>cd8</sup>-KO) were analyzed to unravel the role of T cell Ezh2 in atherosclerosis and T cell-associated immune status.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: <i>EZH2</i> expression is elevated in advanced human atherosclerotic plaques and primarily expressed in the T cell nucleus, suggesting the importance of canonical EZH2 function in atherosclerosis. Ezh2<sup>cd4</sup>-KO, but not Ezh2<sup>cd8</sup>-KO, mice showed reduced atherosclerosis with fewer advanced plaques, which contained less collagen and macrophages, indicating that Ezh2 in CD4<sup>+</sup> T cells drives atherosclerosis. In-depth analysis of CD4<sup>+</sup> T cells of Ezh2<sup>cd4</sup>-KO mice revealed that absence of Ezh2 results in a type 2 immune response with increased Il-4 (interleukin 4) gene and protein expression in the aorta and lymphoid organs. In vitro, <i>Ezh2</i>-deficient T cells polarized macrophages toward an anti-inflammatory phenotype. Single-cell RNA-sequencing of splenic T cells revealed that <i>Ezh2</i> deficiency reduced naive, Ccl5<sup>+</sup> (C-C motif chemokine ligand 5) and regulatory T cell populations and increased the frequencies of memory T cells and invariant natural killer T (iNKT) cells. Flow cytometric analysis identified a shift toward Th2 (type 2 T helper) effector CD4<sup>+</sup> T cells in Ezh2<sup>cd4</sup>-KO mice and confirmed a profound increase in splenic iNKT cells with increased expression of Plzf (promyelocytic leukemia zinc finger), which is the characteristic marker of the iNKT2 subset. Likewise, <i>Zbtb16</i> ([zinc finger and BTB domain containing 16], a Plzf-encoding gene) transcripts were elevated in the aorta of Ezh2<sup>cd4</sup>-KO mice, suggesting an accumulation of iNKT2 cells in the plaque. H3K27me3-chromatin immunoprecipitation followed by quantitative polymerase chain reaction showed that T cell-Ezh2 regulates the transcription of the <i>Il-4</i> and <i>Zbtb16</i> genes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our study uncovers the importance of T cell EZH2 in human and mouse atherosclerosis. Inhibition of Ezh2 in CD4<sup>+</sup> T cells drives type 2 immune responses, resulting in an accumulation of iNKT2 and Th2 cells, memory T cells and anti-inflammatory macrophages that limit the progression of atherosclerosis.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39917842/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250207111255&v=2.18.0.post9+e462414">39917842</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.072384>10.1161/CIRCULATIONAHA.124.072384</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39917842</guid>
<pubDate>Fri, 07 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Cecilia Assunta Bonfiglio</dc:creator>
<dc:creator>Michael Lacy</dc:creator>
<dc:creator>Vasiliki Triantafyllidou</dc:creator>
<dc:creator>Floriana Maria Farina</dc:creator>
<dc:creator>Aleksandar Janjic</dc:creator>
<dc:creator>Katrin Nitz</dc:creator>
<dc:creator>Yuting Wu</dc:creator>
<dc:creator>Venetia Bazioti</dc:creator>
<dc:creator>Irem Avcilar-Kucukgoze</dc:creator>
<dc:creator>Yonara Freire Soares Marques</dc:creator>
<dc:creator>Markus Joppich</dc:creator>
<dc:creator>Mahadia Kumkum</dc:creator>
<dc:creator>Katja Röß</dc:creator>
<dc:creator>Anuroop Venkateswaran Venkatasubramani</dc:creator>
<dc:creator>Axel Imhof</dc:creator>
<dc:creator>Wolfgang Enard</dc:creator>
<dc:creator>Lars Maegdefessel</dc:creator>
<dc:creator>Menno de Winther</dc:creator>
<dc:creator>Christian Weber</dc:creator>
<dc:creator>Donato Santovito</dc:creator>
<dc:creator>Esther Lutgens</dc:creator>
<dc:creator>Dorothee Atzler</dc:creator>
<dc:date>2025-02-07</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Ezh2 Shapes T Cell Plasticity to Drive Atherosclerosis</dc:title>
<dc:identifier>pmid:39917842</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.072384</dc:identifier>
</item>
<item>
<title>Adverse pregnancy outcomes and cardiovascular disease: family matters</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39916373/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250207111255&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 7:ehae905. doi: 10.1093/eurheartj/ehae905. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39916373/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250207111255&v=2.18.0.post9+e462414">39916373</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae905>10.1093/eurheartj/ehae905</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39916373</guid>
<pubDate>Fri, 07 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Aarti Thakkar</dc:creator>
<dc:creator>Neha J Pagidipati</dc:creator>
<dc:date>2025-02-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Adverse pregnancy outcomes and cardiovascular disease: family matters</dc:title>
<dc:identifier>pmid:39916373</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae905</dc:identifier>
</item>
<item>
<title>Adverse pregnancy outcomes, familial predisposition, and cardiovascular risk: a Swedish nationwide study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39916371/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250207111255&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Sisters of women with APOs face a moderately increased risk of CVD, suggesting a genetic and/or environmental influence on the association between APOs and CVDs. These findings underscore the need for evaluating the effectiveness of targeted preventive measures in women with APOs and their sisters.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 7:ehae889. doi: 10.1093/eurheartj/ehae889. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Adverse pregnancy outcomes (APOs) are recognized as significant female-specific risk factors for cardiovascular disease (CVD). A potential shared familial susceptibility between APOs and CVD has been proposed, but not thoroughly explored. This study employs a quasi-experimental family comparison design to investigate shared familial predisposition between APOs and CVD, by assessing risk of CVD in APO-exposed women and their APO-free sisters.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Nationwide population-based cohort study encompassing primiparous women, without prior CVD, with registered singleton births in the Swedish Medical Birth Register between 1992 and 2019, grouped into: women with ≥1 APO (165 628), APO-free sisters (60 769), and unrelated APO-free comparator women (992 108). All study participants were followed longitudinally, through linkage with national health registers, from delivery until 2021, for primary endpoint major adverse cardiac events, and its individual components: ischaemic heart disease, heart failure, and cerebrovascular events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Over a median follow-up of 14 years, APO-exposed women exhibited increased rates of CVDs compared with APO-free comparators. Adverse pregnancy outcome-free sisters exhibited elevated adjusted hazard ratios (aHRs) of major adverse cardiac event {aHR 1.39 [95% confidence interval (CI) 1.13-1.71]}, heart failure [aHR 1.65 (95% CI 1.14-2.39)], and cerebrovascular events [aHR 1.37 (1.04-1.72)] compared with the APO-free comparators, while no significant increase in ischaemic heart disease was observed. Within-family analysis revealed lower CVD rates in APO-free sisters compared with their APO-exposed counterparts, except for no significant difference in cerebrovascular events.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Sisters of women with APOs face a moderately increased risk of CVD, suggesting a genetic and/or environmental influence on the association between APOs and CVDs. These findings underscore the need for evaluating the effectiveness of targeted preventive measures in women with APOs and their sisters.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39916371/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250207111255&v=2.18.0.post9+e462414">39916371</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae889>10.1093/eurheartj/ehae889</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39916371</guid>
<pubDate>Fri, 07 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Ängla Mantel</dc:creator>
<dc:creator>Charlotte Lindblad Wollmann</dc:creator>
<dc:creator>Jonas Faxén</dc:creator>
<dc:creator>Anna Sandström</dc:creator>
<dc:creator>Hanna Mühlrad</dc:creator>
<dc:creator>Olof Stephansson</dc:creator>
<dc:date>2025-02-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Adverse pregnancy outcomes, familial predisposition, and cardiovascular risk: a Swedish nationwide study</dc:title>
<dc:identifier>pmid:39916371</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae889</dc:identifier>
</item>
<item>
<title>Brainstem neuropeptidergic neurons link a neurohumoral axis to satiation</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39914383/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250207111255&amp;v=2.18.0.post9+e462414
      <description>Hunger is evolutionarily hardwired to ensure that an animal has sufficient energy to survive and reproduce. Just as important as knowing when to start eating is knowing when to stop eating. Here, using spatially resolved single-cell phenotyping, we characterize a population of neuropeptidergic neurons in the brainstem's dorsal raphe nucleus (DRN) and describe how they regulate satiation. These neurons track food from sensory presentation through ingestion, integrate these signals with...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Jan 29:S0092-8674(25)00047-9. doi: 10.1016/j.cell.2025.01.018. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Hunger is evolutionarily hardwired to ensure that an animal has sufficient energy to survive and reproduce. Just as important as knowing when to start eating is knowing when to stop eating. Here, using spatially resolved single-cell phenotyping, we characterize a population of neuropeptidergic neurons in the brainstem's dorsal raphe nucleus (DRN) and describe how they regulate satiation. These neurons track food from sensory presentation through ingestion, integrate these signals with slower-acting humoral cues, and express cholecystokinin (CCK). These CCK neurons bidirectionally regulate meal size, driving a sustained meal termination signal with a built-in delay. They are also well positioned to sense and respond to ingestion: they express a host of metabolic signaling factors and are integrated into an extended network known to regulate feeding. Together, this work demonstrates how DRN CCK neurons regulate satiation and identifies a likely conserved cellular mechanism that transforms diverse neurohumoral signals into a key behavioral output.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39914383/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250207111255&v=2.18.0.post9+e462414">39914383</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.01.018>10.1016/j.cell.2025.01.018</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39914383</guid>
<pubDate>Thu, 06 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Srikanta Chowdhury</dc:creator>
<dc:creator>Nachiket G Kamatkar</dc:creator>
<dc:creator>Wendy Xueyi Wang</dc:creator>
<dc:creator>Christa A Akerele</dc:creator>
<dc:creator>Jiahao Huang</dc:creator>
<dc:creator>Junlin Wu</dc:creator>
<dc:creator>Amajindi Nwankpa</dc:creator>
<dc:creator>Charlotte M Kane</dc:creator>
<dc:creator>Varun M Bhave</dc:creator>
<dc:creator>Hao Huang</dc:creator>
<dc:creator>Xiao Wang</dc:creator>
<dc:creator>Alexander R Nectow</dc:creator>
<dc:date>2025-02-06</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Brainstem neuropeptidergic neurons link a neurohumoral axis to satiation</dc:title>
<dc:identifier>pmid:39914383</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.01.018</dc:identifier>
</item>
<item>
<title>Engineered commensals for targeted nose-to-brain drug delivery</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39914382/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250207111255&amp;v=2.18.0.post9+e462414
      <description>Intranasal administration through the olfactory epithelium (OE) presents a direct pathway for brain-targeted therapeutic delivery, although its feasibility is hampered by the anatomical and absorptive limitations of the OE. In this study, we identified Lactobacillus plantarum WCFS1 (Lp), a commensal strain with a natural affinity for the OE and engineered it to function as a vector for cerebral drug delivery. Upon intranasal administration, Lp released specific payload molecules within the OE,...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2025 Feb 3:S0092-8674(25)00046-7. doi: 10.1016/j.cell.2025.01.017. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Intranasal administration through the olfactory epithelium (OE) presents a direct pathway for brain-targeted therapeutic delivery, although its feasibility is hampered by the anatomical and absorptive limitations of the OE. In this study, we identified Lactobacillus plantarum WCFS1 (Lp), a commensal strain with a natural affinity for the OE and engineered it to function as a vector for cerebral drug delivery. Upon intranasal administration, Lp released specific payload molecules within the OE, with subsequent transport and accumulation in the brain. The therapeutic efficacy of Lp was further validated by the recombinant production and secretion of appetite-regulating hormones. When administered intranasally in a murine model of obesity prevention, the engineered Lp significantly alleviated obesity-related symptoms. This was evidenced by decreased appetite, reduced body weight gain, and improved glucose metabolism and fat mass deposition. Our study demonstrates the capability of Lp as an intranasal delivery vehicle, emphasizing its potential for brain-targeted therapeutic applications.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39914382/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250207111255&v=2.18.0.post9+e462414">39914382</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2025.01.017>10.1016/j.cell.2025.01.017</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39914382</guid>
<pubDate>Thu, 06 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Haosheng Shen</dc:creator>
<dc:creator>Nikhil Aggarwal</dc:creator>
<dc:creator>Beiming Cui</dc:creator>
<dc:creator>Guo Wei Foo</dc:creator>
<dc:creator>Yuanzhi He</dc:creator>
<dc:creator>Santosh Kumar Srivastava</dc:creator>
<dc:creator>Shengjie Li</dc:creator>
<dc:creator>Marcus Ze Xian Seah</dc:creator>
<dc:creator>Kwok Soon Wun</dc:creator>
<dc:creator>Hua Ling</dc:creator>
<dc:creator>In Young Hwang</dc:creator>
<dc:creator>Chun Loong Ho</dc:creator>
<dc:creator>Yung Seng Lee</dc:creator>
<dc:creator>Matthew Wook Chang</dc:creator>
<dc:date>2025-02-06</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Engineered commensals for targeted nose-to-brain drug delivery</dc:title>
<dc:identifier>pmid:39914382</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2025.01.017</dc:identifier>
</item>
<item>
<title>Oriental Congress of Cardiology in China: past, present, and future perspectives</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39913255/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250207111255&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 6:ehae848. doi: 10.1093/eurheartj/ehae848. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39913255/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250207111255&v=2.18.0.post9+e462414">39913255</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae848>10.1093/eurheartj/ehae848</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39913255</guid>
<pubDate>Thu, 06 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Yiqing Hu</dc:creator>
<dc:creator>Hao Lu</dc:creator>
<dc:creator>Junbo Ge</dc:creator>
<dc:date>2025-02-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Oriental Congress of Cardiology in China: past, present, and future perspectives</dc:title>
<dc:identifier>pmid:39913255</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae848</dc:identifier>
</item>
<item>
<title>The recent renewed interest among cardiologists in detecting and preventing diabetes is welcomed</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39913237/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250207111255&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 6:ehae833. doi: 10.1093/eurheartj/ehae833. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39913237/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250207111255&v=2.18.0.post9+e462414">39913237</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae833>10.1093/eurheartj/ehae833</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39913237</guid>
<pubDate>Thu, 06 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Anna Norhammar</dc:creator>
<dc:creator>Viveca Ritsinger</dc:creator>
<dc:date>2025-02-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The recent renewed interest among cardiologists in detecting and preventing diabetes is welcomed</dc:title>
<dc:identifier>pmid:39913237</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae833</dc:identifier>
</item>
<item>
<title>Correction to: Erythritol and xylitol and cardiovascular disease risk: a growing concern</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39913117/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250207111255&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 6:ehaf082. doi: 10.1093/eurheartj/ehaf082. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39913117/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250207111255&v=2.18.0.post9+e462414">39913117</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf082>10.1093/eurheartj/ehaf082</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39913117</guid>
<pubDate>Thu, 06 Feb 2025 06:00:00 -0500</pubDate>
<dc:date>2025-02-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: Erythritol and xylitol and cardiovascular disease risk: a growing concern</dc:title>
<dc:identifier>pmid:39913117</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf082</dc:identifier>
</item>
<item>
<title>Correction to: Carotid artery atherosclerosis: mechanisms of instability and clinical implications</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39913114/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250207111255&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2025 Feb 6:ehaf085. doi: 10.1093/eurheartj/ehaf085. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39913114/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250207111255&v=2.18.0.post9+e462414">39913114</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehaf085>10.1093/eurheartj/ehaf085</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39913114</guid>
<pubDate>Thu, 06 Feb 2025 06:00:00 -0500</pubDate>
<dc:date>2025-02-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Correction to: Carotid artery atherosclerosis: mechanisms of instability and clinical implications</dc:title>
<dc:identifier>pmid:39913114</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehaf085</dc:identifier>
</item>
<item>
<title>Loss of Endothelial TRPC1 Induces Aortic Hypercontractility and Hypertension</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39912234/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250207111255&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our results identify endothelial TRPC1 as a previously unclear regulator of vascular changes and blood pressure in both physiological and pathologically obese state, and it is associated with nitric oxide/endothelin-1/c-Fos signaling.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2025 Feb 6. doi: 10.1161/CIRCRESAHA.124.325574. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: The increasing prevalence of obesity-related cardiovascular diseases demands a better understanding of the contribution of different cell types to vascular function for developing new treatment strategies. Previous studies have established a fundamental role of TRPC1 (transient receptor potential channel canonical family member 1) in blood vessels. However, little is known about its functional roles within different cell types.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We generated endothelial-specific TRPC1-deficient and knockin mice and analyzed their changes in vascular function under physiological and pathologically obese state. Wire myography, Ca<sup>2+</sup> image, blood pressure measurements, RNA-sequencing analysis, liquid chromatography-mass spectrometry, immunoblotting, ELISA, luciferase reporter assay, and morphometric assessments were performed to unravel phenotype and molecular changes in response to the absence or presence of endothelial TRPC1.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Loss of endothelial TRPC1 reduced endothelial-dependent relaxation and exaggerated endothelial-dependent contraction in mouse aorta. As expected, loss of endothelial TRPC1 amplified blood pressure and decreased acetylcholine-induced intracellular Ca<sup>2+</sup> concentration rise in the aorta. In endothelial-specific TRPC1-deficient mouse arteries, the mRNA profile identified upregulation of c-Fos. Blockade of c-Fos rescued the impaired vasomotor tone in the aorta of mice deficient in endothelial TRPC1. Endothelial TRPC1-regulated nitric oxide/endothelin-1 production is involved in vascular c-Fos expression. Moreover, knockin of endothelial TRPC1 ameliorated enhanced endothelial-dependent contraction and hypertension in obese mice which is related to alleviated endothelial endothelin-1/c-Fos production and smooth muscle contraction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our results identify endothelial TRPC1 as a previously unclear regulator of vascular changes and blood pressure in both physiological and pathologically obese state, and it is associated with nitric oxide/endothelin-1/c-Fos signaling.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39912234/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250207111255&v=2.18.0.post9+e462414">39912234</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.325574>10.1161/CIRCRESAHA.124.325574</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39912234</guid>
<pubDate>Thu, 06 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Yifei Zhu</dc:creator>
<dc:creator>Yuan Chu</dc:creator>
<dc:creator>Yihui Lan</dc:creator>
<dc:creator>Sheng Wang</dc:creator>
<dc:creator>Yizhi Zhang</dc:creator>
<dc:creator>Yuan Liu</dc:creator>
<dc:creator>Xianfeng Wang</dc:creator>
<dc:creator>Fan Yu</dc:creator>
<dc:creator>Xin Ma</dc:creator>
<dc:date>2025-02-06</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Loss of Endothelial TRPC1 Induces Aortic Hypercontractility and Hypertension</dc:title>
<dc:identifier>pmid:39912234</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.325574</dc:identifier>
</item>
<item>
<title>Induced Cytokinesis Generates Highly Proliferative Mononuclear Cardiomyocytes at the Expense of Contractility</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39912233/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250207111255&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: These results collectively demonstrate that cytokinesis failure mediates cardiomyocyte multinucleation and cell cycle exit of postnatal cardiomyocytes, but may be a protective mechanism to preserve the contractile function of the myocardium.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Circulation</b>. 2025 Feb 6. doi: 10.1161/CIRCULATIONAHA.124.065763. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Cytokinesis is the last step in the eukaryotic cell cycle, which physically separates a mitotic cell into 2 daughter cells. A few days after birth in mouse cardiomyocytes, DNA synthesis occurs without cytokinesis, leading to the majority of cardiomyocytes becoming binucleated instead of generating 2 daughter cells with 1 nucleus each. This results in cell cycle arrest of cardiomyocytes, and the mouse heart is no longer able to regenerate. A longstanding unanswered question is whether binucleation of cardiomyocytes is a result of cytokinesis failure.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: To address this, we generated several transgenic mouse models to determine whether forced induction of cardiomyocyte cytokinesis generates mononucleated cardiomyocytes and restores the endogenous regenerative properties of the myocardium. We focused on 2 complementary regulators of cytokinesis: Plk1 (polo-like kinase 1) and Ect2 (epithelial cell-transformation sequence 2).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: We found that cardiomyocyte-specific transgenic overexpression of constitutively active Plk1(T210D) promotes mitosis and cytokinesis in adult hearts, whereas overexpression of Ect2 alone promotes only cytokinesis. Cardiomyocyte-specific overexpression of both Plk1(T210D) and Ect2 concomitantly (double transgenic) prevents binucleation of cardiomyocytes postnatally and results in widespread cardiomyocyte mitosis, cardiac enlargement, contractile failure, and death before 2 weeks of age. Similarly, doxycycline-inducible cardiomyocyte-specific overexpression of both proteins (inducible double transgenic) in the adult heart results in reversible widespread cardiomyocyte mitosis and contractile failure. Transient induction of both genes in adult mice improves left ventricular systolic function after myocardial infarction.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: These results collectively demonstrate that cytokinesis failure mediates cardiomyocyte multinucleation and cell cycle exit of postnatal cardiomyocytes, but may be a protective mechanism to preserve the contractile function of the myocardium.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39912233/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250207111255&v=2.18.0.post9+e462414">39912233</a> | DOI:<a href=https://doi.org/10.1161/CIRCULATIONAHA.124.065763>10.1161/CIRCULATIONAHA.124.065763</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39912233</guid>
<pubDate>Thu, 06 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Nicholas T Lam</dc:creator>
<dc:creator>Ngoc Uyen Nhi Nguyen</dc:creator>
<dc:creator>Waleed M Elhelaly</dc:creator>
<dc:creator>Ching-Cheng Hsu</dc:creator>
<dc:creator>Ivan Menendez-Montes</dc:creator>
<dc:creator>Feng Xiao</dc:creator>
<dc:creator>Shah R Ali</dc:creator>
<dc:creator>Nelson Vo</dc:creator>
<dc:creator>Nathan Briard</dc:creator>
<dc:creator>Lobna El-Feky</dc:creator>
<dc:creator>Qamar M Omari</dc:creator>
<dc:creator>Alisson C Cardoso</dc:creator>
<dc:creator>Yan Liu</dc:creator>
<dc:creator>Mahmoud Salama Ahmed</dc:creator>
<dc:creator>Shujuan Li</dc:creator>
<dc:creator>Suwannee Thet</dc:creator>
<dc:creator>Chao Xing</dc:creator>
<dc:creator>Lior Zangi</dc:creator>
<dc:creator>Hesham A Sadek</dc:creator>
<dc:date>2025-02-06</dc:date>
<dc:source>Circulation</dc:source>
<dc:title>Induced Cytokinesis Generates Highly Proliferative Mononuclear Cardiomyocytes at the Expense of Contractility</dc:title>
<dc:identifier>pmid:39912233</dc:identifier>
<dc:identifier>doi:10.1161/CIRCULATIONAHA.124.065763</dc:identifier>
</item>
<item>
<title>Amara Yad Image: Cardiac Fibrous Skeleton</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39909685/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250207111255&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Feb 11;85(5):560-561. doi: 10.1016/j.jacc.2024.12.023.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39909685/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250207111255&v=2.18.0.post9+e462414">39909685</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.12.023>10.1016/j.jacc.2024.12.023</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39909685</guid>
<pubDate>Wed, 05 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Kalyanam Shivkumar</dc:creator>
<dc:date>2025-02-05</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Amara Yad Image: Cardiac Fibrous Skeleton</dc:title>
<dc:identifier>pmid:39909685</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.12.023</dc:identifier>
</item>
<item>
<title>Altering Adverse Social Determinants of Cardiovascular Health in Sexual Minorities</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39909684/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250207111255&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Feb 11;85(5):526-527. doi: 10.1016/j.jacc.2024.12.012.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39909684/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250207111255&v=2.18.0.post9+e462414">39909684</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.12.012>10.1016/j.jacc.2024.12.012</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39909684</guid>
<pubDate>Wed, 05 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Caroline Ong</dc:creator>
<dc:creator>Billy A Caceres</dc:creator>
<dc:date>2025-02-05</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Altering Adverse Social Determinants of Cardiovascular Health in Sexual Minorities</dc:title>
<dc:identifier>pmid:39909684</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.12.012</dc:identifier>
</item>
<item>
<title>Social Determinants of Health, Cardiovascular Health, and Mortality in Sexual Minority Individuals in the United States</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39909683/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250207111255&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: An unfavorable SDOH profile was associated with worse CVH scores and higher cardiovascular mortality risk among SM individuals in the United States compared to their heterosexual counterparts.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Feb 11;85(5):515-525. doi: 10.1016/j.jacc.2024.11.026.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Despite recent efforts to address health disparities regarding social determinants of health (SDOH), the intersection between SDOH and cardiovascular health (CVH) outcomes in sexual minority (SM) individuals remain largely underexplored.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study sought to investigate associations between SDOH profile and CVH and mortality outcomes among SM individuals in the United States.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: All participants aged ≥18 years surveyed in the 2013 to 2017 National Health Interview Survey were included, except those with missing data on SM status, any CVH or SDOH domain, or any other covariate. SM status was self-reported and categorized as lesbian/gay, bisexual, or uncertain. Participants' SDOH profile was quantified using a 6-domain (economic stability, neighborhood/physical environment/social cohesion, community and social context, food, education, and health care system), 38-item score, with higher scores indicating greater social deprivation. CVH was adapted from the American Heart Association's Life's Essential 8 framework. Because detailed dietary data were unavailable, a 7-item (hypertension, diabetes mellitus, hypercholesterolemia, smoking, physical inactivity, inadequate sleep, and obesity) CVH score was used, with higher scores indicating worse CVH. Additionally, cardiovascular mortality was ascertained through the National Death Index using death certificate information.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The study sample consisted of 57,182 participants, representing a population of 82,826,690 persons. A worse composite SDOH score was associated with a worse CVH score in both heterosexual (adjusted rate ratio: 1.14; 95% CI: 1.13-1.15; P &lt; 0.001) and SM individuals (adjusted rate ratio: 1.16; 95% CI: 1.12-1.20; P &lt; 0.001), with associations appearing to be potentially stronger in the latter (P<sub>interaction</sub> = 0.042). Subgroup analysis demonstrated consistent associations among gay/lesbian individuals and bisexual individuals, but not in those with other or uncertain sexual orientations. Further exploratory analysis showed that a worse composite SDOH score was significantly associated with higher risk of cardiovascular mortality in both heterosexual (adjusted HR: 1.17; 95% CI: 1.06-1.28; P = 0.002) and SM individuals (adjusted HR: 2.25; 95% CI: 1.24-4.08; P = 0.008), with associations being significantly stronger in the latter (P interaction = 0.006).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: An unfavorable SDOH profile was associated with worse CVH scores and higher cardiovascular mortality risk among SM individuals in the United States compared to their heterosexual counterparts.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39909683/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250207111255&v=2.18.0.post9+e462414">39909683</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.026>10.1016/j.jacc.2024.11.026</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39909683</guid>
<pubDate>Wed, 05 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Danish Iltaf Satti</dc:creator>
<dc:creator>Jeffrey Shi Kai Chan</dc:creator>
<dc:creator>Reed Mszar</dc:creator>
<dc:creator>Adhya Mehta</dc:creator>
<dc:creator>Yaa Adoma Kwapong</dc:creator>
<dc:creator>Raymond Ngai Chiu Chan</dc:creator>
<dc:creator>Olayinka Agboola</dc:creator>
<dc:creator>Erica S Spatz</dc:creator>
<dc:creator>Jared A Spitz</dc:creator>
<dc:creator>Khurram Nasir</dc:creator>
<dc:creator>Zulqarnain Javed</dc:creator>
<dc:creator>Jason A Bonomo</dc:creator>
<dc:creator>Garima Sharma</dc:creator>
<dc:date>2025-02-05</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Social Determinants of Health, Cardiovascular Health, and Mortality in Sexual Minority Individuals in the United States</dc:title>
<dc:identifier>pmid:39909683</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.026</dc:identifier>
</item>
<item>
<title>Evolocumab in Older Individuals: Expanding the Age Horizon</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39909682/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250207111255&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Feb 11;85(5):513-514. doi: 10.1016/j.jacc.2024.11.043.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39909682/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250207111255&v=2.18.0.post9+e462414">39909682</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.043>10.1016/j.jacc.2024.11.043</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39909682</guid>
<pubDate>Wed, 05 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Kalyani Dhar</dc:creator>
<dc:creator>Jeffrey Berger</dc:creator>
<dc:creator>Jonathan Newman</dc:creator>
<dc:creator>Arthur Schwartzbard</dc:creator>
<dc:creator>Astrid Carolina Jara Pernia</dc:creator>
<dc:creator>Howard S Weintraub</dc:creator>
<dc:date>2025-02-05</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Evolocumab in Older Individuals: Expanding the Age Horizon</dc:title>
<dc:identifier>pmid:39909682</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.043</dc:identifier>
</item>
<item>
<title>Long-Term Lipid Lowering With Evolocumab in Older Individuals</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39909681/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250207111255&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Early initiation of long-term evolocumab provides older patients with atherosclerotic cardiovascular disease cardiovascular benefits at least as good as those observed in younger patients, with a more favorable number needed to treat in older patients for reducing a composite endpoint and no significant safety concerns. These findings may be helpful in guiding future recommendations.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Feb 11;85(5):504-512. doi: 10.1016/j.jacc.2024.11.019.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Concerns about the efficacy and safety of intensive low-density lipoprotein cholesterol lowering in older patients have led to weaker recommendations in the U.S. guidelines for patients ≥75 years of age compared to younger patients. Data are sparse on long-term benefits of proprotein convertase subtilisin/kexin type 9 inhibition in older patients.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study aims to assess the long-term benefit of evolocumab among patients aged ≥75 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The FOURIER (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk) trial randomized 27,564 patients who were 18 to 85 years of age with atherosclerotic cardiovascular disease to evolocumab vs placebo with 2.2 years of median follow-up. In the open-label extension (FOURIER-OLE), 6,635 participants were transitioned to open-label evolocumab for an additional 5-year median follow-up. The primary endpoint (cardiovascular death, myocardial infarction, stroke, hospitalization for unstable angina, or coronary revascularization) was compared based on the original allocation to evolocumab vs placebo stratified by age (&lt;75 vs ≥75 years). Analyses were underpowered for individual components of the composite endpoint. The annualized incidence rates for adverse events of interest were calculated for the OLE population across age groups during the parent FOURIER trial by randomized treatment arm and during the combined parent and FOURIER-OLE studies for patients originally allocated to evolocumab.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 27,564 patients, 2,526 (9%) were ≥75 years of age at entry into FOURIER (median age: 77 years [Q1-Q3: 76-79 years]). The median follow-up in FOURIER and FOURIER-OLE was 7.1 years (Q1-Q3: 6.7-7.6 years), with a maximum of 8.7 years. Earlier initiation of evolocumab reduced the rate of the primary endpoint at least as well in older (HR: 0.79; 95% CI: 0.64-0.97) as in younger patients (HR: 0.86; 95% CI: 0.80-0.92; P interaction = 0.43). The absolute risk reductions were 5.4% (95% CI: -2.0% to 12.8%) in older and 2.3% (95% CI: 0.1%-4.5%) in younger patients, leading to numbers needed to treat of 19 and 44, respectively. The annualized incidence rates of safety events generally appeared similar across treatment arms in both age groups.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Early initiation of long-term evolocumab provides older patients with atherosclerotic cardiovascular disease cardiovascular benefits at least as good as those observed in younger patients, with a more favorable number needed to treat in older patients for reducing a composite endpoint and no significant safety concerns. These findings may be helpful in guiding future recommendations.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39909681/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250207111255&v=2.18.0.post9+e462414">39909681</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.019>10.1016/j.jacc.2024.11.019</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39909681</guid>
<pubDate>Wed, 05 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Samer Al Said</dc:creator>
<dc:creator>Michelle L O'Donoghue</dc:creator>
<dc:creator>Xinhui Ran</dc:creator>
<dc:creator>Sabina A Murphy</dc:creator>
<dc:creator>Dan Atar</dc:creator>
<dc:creator>Anthony Keech</dc:creator>
<dc:creator>Jose H Flores-Arredondo</dc:creator>
<dc:creator>Bei Wang</dc:creator>
<dc:creator>Marc S Sabatine</dc:creator>
<dc:creator>Robert P Giugliano</dc:creator>
<dc:date>2025-02-05</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Long-Term Lipid Lowering With Evolocumab in Older Individuals</dc:title>
<dc:identifier>pmid:39909681</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.019</dc:identifier>
</item>
<item>
<title>Does the Mechanism of Weight Loss Matter for Cardiovascular Protection?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39909680/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250207111255&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Feb 11;85(5):501-503. doi: 10.1016/j.jacc.2024.12.020.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39909680/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250207111255&v=2.18.0.post9+e462414">39909680</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.12.020>10.1016/j.jacc.2024.12.020</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39909680</guid>
<pubDate>Wed, 05 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Peder Langeland Myhre</dc:creator>
<dc:creator>Muthiah Vaduganathan</dc:creator>
<dc:date>2025-02-05</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Does the Mechanism of Weight Loss Matter for Cardiovascular Protection?</dc:title>
<dc:identifier>pmid:39909680</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.12.020</dc:identifier>
</item>
<item>
<title>Making Secondary Prevention the Primary Focus for Cardiovascular Disease Control</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39909679/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250207111255&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Feb 11;85(5):451-453. doi: 10.1016/j.jacc.2024.11.040.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39909679/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250207111255&v=2.18.0.post9+e462414">39909679</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.040>10.1016/j.jacc.2024.11.040</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39909679</guid>
<pubDate>Wed, 05 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Oyere K Onuma</dc:creator>
<dc:date>2025-02-05</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Making Secondary Prevention the Primary Focus for Cardiovascular Disease Control</dc:title>
<dc:identifier>pmid:39909679</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.040</dc:identifier>
</item>
<item>
<title>PURE Evidence in Plain Sight: The Highs, Lows, and Gaps in Secondary Cardiovascular Prevention</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39909678/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250207111255&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Feb 11;85(5):448-450. doi: 10.1016/j.jacc.2024.11.034.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39909678/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250207111255&v=2.18.0.post9+e462414">39909678</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.11.034>10.1016/j.jacc.2024.11.034</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39909678</guid>
<pubDate>Wed, 05 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Abhishek Chaturvedi</dc:creator>
<dc:creator>Dorairaj Prabhakaran</dc:creator>
<dc:date>2025-02-05</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>PURE Evidence in Plain Sight: The Highs, Lows, and Gaps in Secondary Cardiovascular Prevention</dc:title>
<dc:identifier>pmid:39909678</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.11.034</dc:identifier>
</item>
<item>
<title>Secondary Prevention Medications in 17 Countries Grouped by Income Level (PURE): A Prospective Cohort Study</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39909677/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250207111255&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Globally and in most country income-level groups, the use of medications for secondary CVD prevention has been low, with little improvement over time.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Feb 11;85(5):436-447. doi: 10.1016/j.jacc.2024.10.121.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: It is unclear whether global use of medications for secondary cardiovascular (CVD) prevention is improving over time.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">OBJECTIVES: This study across 17 high-, middle- and low-income countries described variations in secondary CVD prevention medication use over a median follow-up of 12 years.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: In the multinational PURE (Prospective Urban Rural Epidemiology) cohort study, we conducted a repeated cross-sectional analysis to examine temporal variations in the use of secondary prevention medications in participants with CVD. In participants with coronary artery disease, we focused on antiplatelet agents, statins, renin-angiotensin system (RAS) inhibitors, and β-blockers. In participants with stroke, we focused on antiplatelet agents, statins, RAS inhibitors, and other blood pressure-lowering drugs. Medications were collected at baseline and on 4 subsequent follow-up visits.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The analysis included 7,409 participants with a diagnosis of CVD at the baseline visit, 8,792 at the second visit, 9,236 at the third visit, 11,082 at the fourth visit, and 11,677 at the last visit. The median age at baseline was 58.0 years, and 52.9% of the participants were female. The median follow-up was 12 years, with the median year of the baseline visit in 2007 and the fifth visit in 2019. Over this period, use of 1 or more classes of medications for secondary CVD prevention was 41.3% (95% CI: 40.2%-42.4%) at baseline, peaked at 43.1% (95% CI: 42.0%-44.1%), and then decreased to 31.3% (95% CI: 30.4%-32.1%) by the last study visit. In high-income countries, this use decreased from 88.8% (95% CI: 86.6%-91.0%) to 77.3% (95% CI: 74.9%-79.6%). In upper-middle-income countries, this use increased from 55.0% (95% CI: 52.8%-57.3%) to 61.1% (95% CI: 59.1%-63.1%). In lower-middle-income countries, use of at least 1 class of medications was 29.5% (95% CI: 28.1%-30.9%) at baseline, peaked at 31.7% (95% CI: 30.4%-33.1%), and then decreased to 13.4% (95% CI: 12.5%-14.2%) by the last visit. In low-income countries, use of at least 1 class of medications was 20.8% (95% CI: 18.1%-23.5%) at baseline, peaked at 47.3% (95% CI: 44.8%-49.9%), and then decreased to 27.5% (95% CI: 25.2%-29.9%) by the last study visit.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Globally and in most country income-level groups, the use of medications for secondary CVD prevention has been low, with little improvement over time.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39909677/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250207111255&v=2.18.0.post9+e462414">39909677</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.10.121>10.1016/j.jacc.2024.10.121</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39909677</guid>
<pubDate>Wed, 05 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Philip Joseph</dc:creator>
<dc:creator>Álvaro Avezum</dc:creator>
<dc:creator>Chinthanie Ramasundarahettige</dc:creator>
<dc:creator>Prem K Mony</dc:creator>
<dc:creator>Rita Yusuf</dc:creator>
<dc:creator>Khawar Kazmi</dc:creator>
<dc:creator>Andrzej Szuba</dc:creator>
<dc:creator>Patricio Lopez-Jaramillo</dc:creator>
<dc:creator>Maria Luz Diaz</dc:creator>
<dc:creator>Afzal Hussein Yusufali</dc:creator>
<dc:creator>Sadi Gulec</dc:creator>
<dc:creator>Roya Kelishadi</dc:creator>
<dc:creator>Li Wei</dc:creator>
<dc:creator>Jephat Chifamba</dc:creator>
<dc:creator>Fernando Lanas</dc:creator>
<dc:creator>Thandi Puoane</dc:creator>
<dc:creator>Ambigga Krishnapillai</dc:creator>
<dc:creator>Sumathy Rangarajan</dc:creator>
<dc:creator>Salim Yusuf</dc:creator>
<dc:creator>PURE Investigators</dc:creator>
<dc:date>2025-02-05</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Secondary Prevention Medications in 17 Countries Grouped by Income Level (PURE): A Prospective Cohort Study</dc:title>
<dc:identifier>pmid:39909677</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.10.121</dc:identifier>
</item>
<item>
<title>Advancing Prevention: Insights From JACC's Focus Issue</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/39909676/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20250207111255&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">J Am Coll Cardiol. 2025 Feb 11;85(5):433-435. doi: 10.1016/j.jacc.2024.12.024.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/39909676/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20250207111255&v=2.18.0.post9+e462414">39909676</a> | DOI:<a href=https://doi.org/10.1016/j.jacc.2024.12.024>10.1016/j.jacc.2024.12.024</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:39909676</guid>
<pubDate>Wed, 05 Feb 2025 06:00:00 -0500</pubDate>
<dc:creator>Harlan M Krumholz</dc:creator>
<dc:date>2025-02-05</dc:date>
<dc:source>Journal of the American College of Cardiology</dc:source>
<dc:title>Advancing Prevention: Insights From JACC's Focus Issue</dc:title>
<dc:identifier>pmid:39909676</dc:identifier>
<dc:identifier>doi:10.1016/j.jacc.2024.12.024</dc:identifier>
</item>





























</channel>
</rss>